Engineering mRNA CAR-T Cells for Cancer Immunotherapy.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Adoptive T-cell therapy is a promising cancer immunotherapy.
• Isolating tumor-specific cytotoxic T cells is challenging and time-consuming.
• Genetically modifying T cells with chimeric antigen receptors (CARs) offers an alternative approach.

Purpose of the Study:

• To outline protocols for large-scale T-cell expansion and medium-scale production of mRNA CAR-T cells.
• To demonstrate the use of electroporation as a delivery method for CAR mRNA.
• To present two model CAR systems targeting CD19 and a tumor antigen relevant to hematological malignancies and solid tumors.

Main Methods:

• Large-scale T-cell expansion.
• Medium-scale production of CAR-T cells using messenger RNA (mRNA).
• Electroporation as the CAR mRNA delivery method.

Main Results:

• Established protocols for scalable CAR-T cell production.
• Demonstrated successful delivery of CAR mRNA via electroporation.
• Utilized CARs targeting CD19 and a broader tumor antigen for model systems.

Conclusions:

• The presented protocols facilitate the production of mRNA CAR-T cells for cancer immunotherapy.
• Electroporation provides an effective method for CAR mRNA delivery.
• The developed CAR-T cell systems show potential for targeting various cancers, including hematological malignancies and solid tumors.